The basic properties of bone marrow mesenchymal stromal cells from donors: Superficial markers

Terapevticheskii Arkhiv

Volumn 82, Issue 7, 2010, Pages 52-56

  Svinareva, D A ^a   Shipunova, I N ^a   Olshanskaya, Yu V ^a,b   Momotyuk, K S ^a   Drize, N I ^a   Savchenko, V G ^a  

^a NATIONAL RESEARCH CENTER FOR HEMATOLOGY   (Russian Federation)

^b Oncology   (Russian Federation)

Author keywords

Chromosomal analysis; Flow cytofluorometry; Mesenchymal stromal cells

Indexed keywords

BIOLOGICAL MARKER; CD146 ANTIGEN; MCAM PROTEIN, HUMAN; NERVE GROWTH FACTOR RECEPTOR; NERVE PROTEIN; NGFR PROTEIN, HUMAN;

ARTICLE; BONE MARROW CELL; CELL DIFFERENTIATION; CHROMOSOMAL INSTABILITY; CYTOLOGY; DONOR; FLOW CYTOMETRY; GENETICS; HUMAN; IMMUNOLOGY; MESENCHYMAL STEM CELL; METAPHASE; PATHOLOGY; STROMA CELL;

ANTIGENS, CD146; BIOLOGICAL MARKERS; BONE MARROW CELLS; CELL DIFFERENTIATION; CHROMOSOMAL INSTABILITY; FLOW CYTOMETRY; HUMANS; MESENCHYMAL STEM CELLS; METAPHASE; NERVE TISSUE PROTEINS; RECEPTORS, NERVE GROWTH FACTOR; STROMAL CELLS; TISSUE DONORS;

EID: 77956961551     PISSN: 00403660     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Caplan A. I. Mesenchymal stem cells. J. Orthop. Res. 1991; 9 (5): 641-650.
2. Horwitz E. M., Le Blanc K., Dominici M. et al. Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement. Cytotherapy 2005; 7 (5): 393-395. (Pubitemid 41671625)
3. Jorgensen C., Gordeladze J., Noel D. Tissue engineering through autologous mesenchymal stem cells. Curr. Opin. Biotechnol. 2004; 15 (5): 406-410.
4. Caplan A. I. Osteogenesis imperfecta, rehabilitation medicine, fundamental research and mesenchymal stem cells. Connect. Tissue Res. 1995; 31 (4): S9-S14.
5. Horwitz E. M., Prockop D. J., Fitzpatrick L. A. et al. Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nat. Med. 1999; 5 (3): 309-313.
6. Deans R. J., Moseley A. B. Mesenchymal stem cells: biology and potential clinical uses. Exp. Hematol. 2000; 28 (8): 875-884.
7. Vercelli A., Mereuta O. M., Garbossa D. et al. Human mesenchymal stem cell transplantation extends survival, improves motor performance and decreases neuroinflammation in mouse model of amyotrophic lateral sclerosis. Neurobiol. Dis. 2008; 31 (3): 395-405.
8. Tyndall A., Uccelli A. Multipotent mesenchymal stromal cells for autoimmune diseases: teaching new dogs old tricks. Bone Marrow Transplant. 2009; 43 (11): 821-828.
9. Le Blanc K., Rasmusson I., Sundberg B. et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004; 363 (9419): 1439-1441. (Pubitemid 38586721)
10. Deeg H. J. How I treat refractory acute GVHD. Blood 2007; 109 (10): 4119-4126.
11. Jones B. J., McTaggart S. J. Immunosuppression by mesenchymal stromal cells: from culture to clinic. Exp. Hematol. 2008; 36 (6): 733-741.
12. Rosland G. V., Svendsen A., Torsvik A. et al. Long-term cultures of bone marrow-derived human mesenchymal stem cells frequently undergo spontaneous malignant transformation. Cancer Res. 2009; 69 (13): 5331-5339.
13. Rubio D., Garcia-Castro J., Martin M. C. et al. Spontaneous human adult stem cell transformation. Cancer Res. 2005; 65 (8): 3035-3039.
14. Wang Y., Huso D. L., Harrington J. et al. Outgrowth of a transformed cell population derived from normal human BM mesenchymal stem cell culture. Cytotherapy 2005; 7 (6): 509-519. (Pubitemid 43078081)
15. Bernardo M. E., Zaffaroni N., Novara F. et al. Human bone marrow derived mesenchymal stem cells do not undergo transformation after long-term in vitro culture and do not exhibit telomere maintenance mechanisms. Cancer Res. 2007; 67 (19): 9142-9149. (Pubitemid 47535900)
16. Meza-Zepeda L. A., Noer A., Dahl J. A. et al. High-resolution analysis of genetic stability of human adipose tissue stem cells cultured to senescence. J. Cell Mol. Med. 2008; 12 (2): 553-563.
17. Lange C., Cakiroglu F., Spiess A. N. et al. Accelerated and safe expansion of human mesenchymal stromal cells in animal serum-free medium for transplantation and regenerative medicine. J. Cell Physiol. 2007; 213 (1): 18-26. (Pubitemid 47378788)
18. Seabright M. A rapid banding technique for human chromosomes. Lancet 1971; 2 (7731): 971-972.
19. Dominici M., Le Blanc K., Mueller I. et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006; 8 (4): 315-317.
20. Sacchetti B., Funari A., Michienzi S. et al. Self-renewing osteoprogenitors in bone marrow sinusoids can organize a hematopoietic microenvironment. Cell 2007; 131 (2): 324-336.
21. Jones E. A., Kinsey S. E., English A. et al. Isolation and characterization of bone marrow multipotential mesenchymal progenitor cells. Arthritis. Rheum. 2002; 46 (12): 3349-3360.
22. Quirici N., Soligo D., Bossolasco P. et al. Isolation of bone marrow mesenchymal stem cells by anti-nerve growth factor receptor antibodies. Exp. Hematol. 2002; 30 (7): 783-791.
23. Buhring H. J., Battula V. L., Treml S. et al. Novel markers for the prospective isolation of human MSC Ann. N. Y. Acad. Sci. 2007; 1106: 262-271.
24. Zhang Z. X., Guan L. X., Zhang K. et al. Cytogenetic analysis of human bone marrow-derived mesenchymal stem cells passaged in vitro. Cell Biol. Int. 2007; 31 (6): 645-648.
25. Mareschi K, Ferrero I., Rustichelli D. et al. Expansion of mesenchymal stem cells isolated from pediatric and adult donor bone marrow. J. Cell Biochem. 2006; 97 (4): 744-754.
26. Little M. P. A comparison of the degree of curvature in the cancer incidence dose-response in Japanese atomic bomb survivors with that in chromosome aberrations measured in vitro. Int. J. Radiat. Biol. 2000; 76 (10): 1365-1375.